

## Data Sharing Statement

|                     |  |   |
|---------------------|--|---|
| <b>Article Info</b> | <a href="http://dx.doi.org/10.21037/tcr-20-1333">http://dx.doi.org/10.21037/tcr-20-1333</a>  |   |
| <b>Item</b>         | <b>Question</b>  | <b>Authors' Response<br/>(place "-" if not applicable)</b>  |
| 1                   | Would you like to share data collected for your study to others?   | Yes   |
| 2                   | If not, would you like to share the reason for your decision?  | -   |
| 3                   | What data in particular will be shared?  | The survival data and response rate will be shared.   |
| 4                   | Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.                       |
| 5                   | When will data availability begin?   | From the publication date.  |
| 6                   | When will data availability end?   | Two years within the publication date, since the technique or survival date may be updated over time.                               |
| 7                   | To whom will you share the data?   | Medical oncologists   |
| 8                   | For what type of analysis or purpose?  | For analysis to evaluate the efficacy and safety of patients received PD-1 inhibitor and apatinib as second- or third-line therapy. |
| 9                   | How or where can the data/documents be obtained?   | Emails could be sent to the address below to obtain the shared data: weiqingmd@163.com.   |
| 10                  | Any other restrictions?  | We may balance the potential benefits and risks for each request and then provide the data that could be shared.                    |